

Ten Things Your Doctor Doesn't Know About Cholesterol #3

We hear in the news and in commercials that plant sterols are good for us and lower cholesterol levels. We are even fortifying certain foods and even baby aspirin with these phytosterols. These phytosterols may be more atherogenic than cholesterol in certain groups of people. Stanols on the other hand are good for everyone and do lower cholesterol levels. I am also perplexed that the majority of physicians that I have encountered also do not know the difference between a sterol and a stanol. --- I want to start with some definitions. Cholesterol is a sterol. A sterol is a steroid with an alcohol group attached to it. Stanols are saturated or reduced sterols that are similar to cholesterol but have a methyl or an ethyl group attached to it. This difference minimizes stanol absorption in the intestines. Cholestanol is a stanol. Cholesterol can be broken down by the liver into cholestanol and thus is a by-product of cholesterol metabolism. If sterols or stanols are esterified (combined with fatty acids), then they can be incorporated into margarine. We consume many sterols from plant sources (sitosterol, campesterol, and stigmasterol), shellfish (desmosterol and fucosterol) and animal sources (cholesterol). All of these sterols with the exception of cholesterol are collectively referred to as noncholesterol sterols. Collectively, these sterols can be called phytosterols. Sitosterol represents about 80% of all noncholesterol sterols in the diet and is the most well known noncholesterol sterol in the diet. When fats (triglycerides) enter the intestine in our food, they are broken down into their basic building blocks. The main breakdown products are called fatty acids. These fatty acids and sterols from dietary sources are packaged into what is called a micelle. These micelles "ferry" these fatty acids and sterols to the intestinal lining (epithelium) and then they are absorbed by passive diffusion into the intestinal cells. Passive diffusion is a biological principle that substances flow through a semi-permeable from an area of higher concentration to an area of lesser concentration. There is no pump required to get them out of the intestine and ultimately into the bloodstream. Most humans absorb about 50% of sterols in the intestines but some people are what is termed "hyperabsorbers" (60-80%) and hypoabsorbers. There is no doubt that the noncholesterol sterols are effective in reducing cholesterol levels by blocking absorption from the intestine. Evolution has gone to great lengths to keep noncholesterol sterols out of the human body so almost immediately after absorption some of the cholesterol and virtually all of the noncholesterol sterols are pumped back into the intestinal lumen (cavity) via something called ATP binding cassette transporters, ABCG5/G8. As I previously stated, only about 50-55% of ingested cholesterol makes it into chylomicrons in order to be transported to the liver for processing. These ATP binding cassette half-transporters G5 and G8, facilitate transport of sterols out of cells of both the intestine and liver into the intestinal lumen and into the bile. Any sterols that are not pumped back into the intestine become part of the contents of the intestinally produced chylomicron

particle that transports lipids to the liver. 70% of the cholesterol in the body is transported as an ester, not as free cholesterol, and this is called cholesterol ester. Any noncholesterol sterols that were not sent back to the intestine via ABCG5/G8 also become part of the chylomicron and thus gain entry into the bloodstream. Noncholesterol sterols are not esterified as humans do not have the enzymes necessary for that. When these unesterified sterols get into an arterial wall, they are more atherogenic than cholesterol (an esterified sterol). This means they have a greater artery clogging potential than does cholesterol. If one lacks these transporters (homozygote), all sterols are absorbed and none are pumped back out: this is a very rare homozygous condition leading to the disease called sitosterolemia or phytosterolemia. It is associated with severe atherosclerosis, as noncholesterol sterols (which cannot be esterified) are more atherogenic than cholesterol. Heterozygotes, people who have some transporter function, eliminate some but not all of these phytosterols. Stanols do not require these transporters to get back into these intestines. This is the reason that they are safe and effective to reduce cholesterol. Stanols are commercially available in the supermarket in a product called Benecol. We are now beginning to understand that not everyone has perfect functioning G5/G8 transporters and noncholesterol sterols get into some people: especially those with family history of CAD (coronary artery disease) and postmenopausal women. These sterols may contribute to their atherosclerosis. Such patients have slightly elevated sitosterol and campesterol levels (no where near what the homozygous patients have). As clinicians have no way of knowing which of our patients may be over absorbing sterols without measuring sitosterol levels. This is not routinely done in clinical practice. Although sterols are artificially added to many foods and bay aspirin, it should be clear that in some people they may do more damage than does cholesterol. Prior to the introduction of ezetimibe (Zetia), there was no way to effectively block the absorption of cholesterol and noncholesterol sterols. I have posted previously on this blog a paper called ezetimibe (Zetia). Zetia typically reduces the absorption of all sterols by 50%. It is FDA approved to lower cholesterol and noncholesterol sterols (sitosterolemia). Since the majority of cholesterol is produced in the liver, Zetia does not have a great effect in lowering ingested cholesterol. Statins are the first line therapy in treating high cholesterol. It was shown in a trial called the 4S trial that as a statin lowers cholesterol levels and block its production, intestinal absorption of cholesterol and noncholesterol sterols increases. Using Zetia would eliminate this problem.

In Summary, noncholesterol sterols serve no physiologic function in man. All sterols are atherogenic if they accumulate in the arterial wall. Stanols are saturated sterols. They are not absorbed and can be used therapeutically to reduce cholesterol absorption from the intestine.